Current Progress in CAR-T Cell Therapy for Solid Tumors.
Ma S, Li X, Wang X, Cheng L, Li Z, Zhang C, Ye Z, Qian Q. · 2019
Read Current Progress in CAR-T Cell Therapy for Solid Tumors. by Ma S, Li X, Wang X, Cheng L, Li Z, Zhang C, Ye Z, Qian Q. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6854376.txt.
Introduction
Ma and co-authors review CAR-T cell therapy for solid tumours, in the International Journal of Biological Sciences. In this treatment, a patient's T cells are engineered to hunt cancer. Two such products, Kymriah and Yescarta, won United States approval for blood cancers. Solid tumours, which make up most cancers, have resisted the same approach.
The review explains why. Engineered cells struggle to enter solid tumours, and the tissue around them suppresses attack. Targets shared with healthy tissue add risk. Most current work tries to strengthen the cells or disarm that hostile setting. The authors also cover the diagnostic tests that travel with these therapies, a topic they find neglected.
Catalog record
| CREATOR | Ma S, Li X, Wang X, Cheng L, Li Z, Zhang C, Ye Z, Qian Q. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 66 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Current Progress in CAR-T Cell Therapy for Solid Tumors By Shuo Ma, Xinchun Li, Xinyue Wang, Liang Cheng, Zhong Li, Changzheng Zhang, Zhenlong Ye, Qijun Qian Published in: International Journal of Biological Sciences DOI: 10.7150/ijbs.34213 ABSTRACT Abstract Cancer immunotherapy by chimeric antigen receptor-modified T (CAR-T) cells has shown exhilarative clinical efficacy for hematological malignancies. Recently two CAR-T cell based therapeutics, Kymriah (Tisagenlecleucel) and Yescarta (Axicabtagene ciloleucel) approved by US FDA (US Food and Drug Administration) are now used for treatment of B cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) respectively in the US. Despite the progresses made in treating hematological malignancies, challenges still remain for use of CAR-T cell therapy to treat solid tumors. In this landscape, most studies have primarily focused on improving CAR-T cells and overcoming the unfavorable effects of tumor microenvironment on solid tumors. To further understand the current status and trend for developing CAR-T cell based therapies for various solid tumors, this review emphasizes on CAR-T techniques, current obstacles, and strategies for application, as well as necessary companion diagnostics for treatment of solid tumors with CAR-T cells. Keywords: CAR-T cells, chimeric antigen receptor, solid tumors, companion diagnostics, CTC INTRODUCTION Immunotherapy with CAR-T cells has achieved tremendous successes in treatment of hematological malignancies. Two CD19-targeting CAR-T cell products, Kymriah from the Novartis (East Hanover, NJ USA) and Yescarta from the Kite Pharma (Santa Monica, CA USA), have been approved by the US FDA for treating B cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL), respectively 1. However, due to intricacies of solid tumors and their locations in the human body, treatment of solid tumors with CAR-T cells is facing multiple obstacles, such as the hostile tumor microenvironment, on-tumor/off-tumor toxicities, and undesired antigen specificity 2. Many strategies and approaches have been tried to overcome these obstacles, including arming CAR-T cells with knock-out of PD-1 expression or secretion of cytokines/chemokines and using CAR-T cells in combination with other treatments 3-5. Despite these efforts, there are still no CAR-T cells clinically approved for solid tumor treatment so far. Encouragingly and optimistically, in this landscape, more than forty clinical trials in treatment of solid tumors by CAR-T cells have been registered in China alone (Table 1) 6. [Table: Clinical trials in treatment of solid tumors in China by CAR-T cells] Beside the focuses on the aspects of treatment, companion diagnostics are increasingly recognized as playing important roles in patient screening, treatment regimen, efficacy evaluation, and real-time monitoring of CAR-T cell therapies. Therefore, in this review, we focus on current CAR-T techniques, obstacles, strategies for overcoming these obstacles, as well as necessary companion diagnostics in treatment of solid tumors with CAR-T cells. OVERVIEW OF CAR-T TECHNIQUES Chimeric antigen receptor (CAR) is the core component of CAR-T, which endows T cells with the ability to recognize tumor antigens in a HLA-independent manner and enables them to recognize more extensive target antigens than natural T cell surface receptor (TCR) 7. A basic CAR includes a tumor-associated antigen (TAA) binding domain (usually from the scFv fragment of antigen-binding region of the monoclonal antibody), an extracellular hinge domain, a transmembrane domain and an intracellular signal domain 7, 8. The activation of T cells mediated by the first generation of CAR is accomplished by the tyrosine activation motif on CD3ζ chain or FcεRIγ 9. CD3ζ chain can provide “signal I” for T cell activation, cytolysis, regulation of IL-2 secretion and anti-tumor activity in vivo 10, 11. However, the anti-tumor activity of the first generation of CAR modified T cells is limited in vivo, and the decreased proliferation of T cells ultimately leads to apoptosis 12, 13. The second generation of CAR adds a new costimulatory signal in the intracellular region, which enlarges the original “signal I” derived from TCR/CD3 complex 14, 15. Many studies have shown that compared with the first generation of CAR, the second generation of CAR carrying “signal II” has the same antigen specificity, increased T cell proliferation and cytokine secretion, enhanced secretion of anti-apoptotic proteins, and delayed cell death. The ubiquitously used costimulatory molecule is CD28 16, 17, which have been gradually been replaced with CD137 (4-1BB) 18. In addition, an idea of using NK cell receptor CD244 has also been proposed to promote sustained activation and proliferation of CAR-T cells 19. In order to further improve the design of CAR, many studies began to focus on the development of the third generation of CAR, including not only “signal I”, “signal II”, but also additional costimulatory signals. Studies using different targets and costimulatory signals were conducted to compare the results of the second and third generation of CARs and obtained quite encouraging experimental results 20, 21. Zhong et al. combined CD28 and 4-1BB costimulatory signaling domains to construct a CAR specific for prostate-specific membrane antigen (PSMA). This group demonstrated that the CAR they constructed was able to induce strongest PI3K/Akt activation and Bcl-XL expression in vitro, and the least apoptosis in transduced peripheral blood CD8+ T cells 20. Targeting a different tumor marker, MUC1, Wilkie et al. designed a CAR containing a fused CD28/OX40/CD3ζ endodomain. Using the engineered CAT-T cells and upon MUC1 stimulation, they showed that these CAR-T cells were able to secrete proinflammatory cytokines indicative of both type-1 (IFN-γ) and Th17 (IL-17) differentiation in vitro. It was noteworthy that IL-17 has been known as tissue destructive cytokine in autoimmune disease animal models, although its anti-tumor effect is still to be elucidated 20, 21. Up to date, it is still uncertain which design is better between the second generation and the third generation of CAR. Additionally, the second and third generations of CARs have their own on-going clinical trials in the US, China and Europe, and the development and outcome of these clinical trials are being closely watched. OBSTACLES IN TREATING SOLID TUMORS WITH CAR-T CELLS 1. CAR-T cells traffick to the tumor sites To bind to their target proteins on the surface of tumors, CAR-T cells first need to traffick to tumor sites. This is the fundamental prerequisite for T cell immunotherapy to work properly. Unlike the hematological malignancies, in the case of solid tumors, T cells trafficking to and infiltrating into tumor sites are oftentimes greatly limited by the immunosuppresive microenvironment 22. Also unlike hematological malignancies that are easy to be targeted and reached by CAR-T cells, some of chemokines such as CXCL1 23, CXCL12, and CXCL5 24, 25 secreted by solid tumors prevent T cells from trafficking toward and infiltrating into the tumor lesions. Due to lack of corresponding chemokine receptors expressed on T cells, it is difficult for them to traffic and infiltrate into tumor sites, drastically impeding the ability of CAR-T cells for their designed immuno-cytotoxicity for killing tumor cells. Therefore, in order to overcome this obstacle, T cell will need to be modified to express chemokine receptor that matches the corresponding tumor-derived chemokine. An early study conducted by Kershaw et al. demonstrated that chemokine receptor (CXCL1 receptor)-engineered T cells can greatly drive themselves to migrate toward melanoma cells 23. This study demonstrated the feasibility that T cell traffic can be re-directed to tumor sites by chemokines secreted by tumor cells. 2. CAR-T cells infiltrate into tumors Once CAR-T cells